Antisense Oligomer EP4342498A1, Chiba University, published 8th Apr

The EPO published Chiba University's patent application EP4342498A1 for an antisense oligomer composition on 8 April 2026. The patent covers pharmaceutical compositions comprising the antisense oligomer, gene therapy vectors (AAV-based), and pharmaceutical formulations, with therapeutic applications spanning cardiovascular disease, metabolic disorders (hyperlipidaemia, diabetes, diabetic complications), ophthalmic conditions, and dermatological applications including hair growth disorders. IPC classifications span A61K (medicinal preparations), A61P (therapeutic activity), C12N (biotechnology/nucleic acid sequences), and C12N 15/86 (viral vectors).

For companies developing antisense therapeutics, gene therapy products, or pharmaceuticals in the covered therapeutic areas (cardiovascular, metabolic, dermatological), this patent publication signals the existence of potential blocking IP rights in the designated Contracting States (EU member states and others). Competitors should evaluate freedom-to-operate, consider design-around strategies, or explore licensing opportunities to avoid infringement in these jurisdictions.